Company Description
Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide.
The company operates in three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals.
It cultivates, processes, and supplies medicinal-grade cannabis flower, as well as cannabis derived medical and wellness products.
The company also offers food and beverage, nutraceutical, cannabis accessories and technology, personal care, and wellness products; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; and cannabis consumption accessories, as well as personal storage and travel accessories for the vape and dry herbs.
In addition, it manufactures and distributes pharmaceutical goods and medical cannabis products to treat a range of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants.
The company sells its products under the JustCBD, Vessel, and Phatebo brand names. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.
| Country | United States |
| Founded | 2019 |
| IPO Date | May 11, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Clifford Starke |
Contact Details
Address: 3406 SW 26th Terrace, Suite C-1 Fort Lauderdale, Florida 33132 United States | |
| Phone | 954 842 4989 |
| Website | floragrowth.com |
Stock Details
| Ticker Symbol | FLGC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001790169 |
| CUSIP Number | 339764102 |
| ISIN Number | CA3397642016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Clifford A. Starke | Chief Executive Officer and Director |
| Samuel Dorf Esq. | Executive Chairman of the Board |
| Dany Vaiman | Chief Financial Officer |
| Dr. Manfred Ziegler | Managing Director |
| Patrick Moloney | Head of Product Development |
| Aaron Atin | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2025 | D | Notice of Exempt Offering of Securities |
| May 6, 2025 | DEF 14A | Other definitive proxy statements |
| May 5, 2025 | ARS | Filing |
| May 2, 2025 | SCHEDULE 13G | Filing |
| May 2, 2025 | 8-K | Current Report |
| Apr 29, 2025 | SCHEDULE 13G/A | Filing |
| Apr 15, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 28, 2025 | EFFECT | Notice of Effectiveness |
| Mar 25, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Mar 24, 2025 | 10-K | Annual Report |